Arcturus Therapeutics Holdings, Inc. (ARCT)
7.73
+0.20
(+2.66%)
USD |
NASDAQ |
Jan 13, 11:51
Arcturus Therapeutics Holdings Research and Development Expense (Quarterly): 19.38M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 12.98M |
| Perspective Therapeutics, Inc. | 19.56M |
| Novavax, Inc. | 98.17M |
| Sangamo Therapeutics, Inc. | 28.69M |
| Myomo, Inc. | 1.528M |